# Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy

## TL;DR

This paper reviews how PD-1 and LAG-3 work together to weaken T-cell function in tumors and explores how blocking both can improve cancer immunotherapy.

## Contribution

The paper provides a systematic synthesis of PD-1/LAG-3 synergy mechanisms and dual blockade therapy advances.

## Key findings

- PD-1 and LAG-3 synergistically suppress T-cell function through distinct signaling pathways.
- Dual blockade with bispecific antibodies has shown clinical promise, including approval for melanoma.
- Challenges remain in achieving consistent response rates and managing adverse events.

## Abstract

PD-1 and LAG-3 are immune checkpoint molecules frequently co-expressed in the tumor microenvironment, where they synergistically drive T-cell exhaustion and immune escape. Dual blockade of these pathways represents a promising strategy to overcome immunotherapy resistance.

This review systematically synthesizes mechanistic studies on PD-1/LAG-3 synergy and summarizes preclinical and clinical advances in dual blockade therapies, with emphasis on bispecific antibodies and combination trial data.

PD-1 and LAG-3 cooperatively suppress T-cell function via complementary signaling pathways. Combined inhibition substantially restores antitumor immunity. A PD-1/LAG-3 bispecific antibody has been approved for melanoma, with numerous trials ongoing across other malignancies.

Despite demonstrated efficacy, challenges including variable response rates, resistance mechanisms, and immune-related adverse events remain. Future efforts should prioritize biomarker identification and regimen optimization to enable precision application of dual blockade.